SEC Form 4/A · accession 0001177648-18-000034
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Nathalie Adda
Officer — Sr. VP & Chief Medical Officer
Period of report
Jul 18, 2018
Accepted (ET)
Sep 21, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF6,F2 | Jul 18, 2018 | S | 1,185 | $123.7155 | D | 5,370 | D | |
| Common StockF3,F6 | Jul 18, 2018 | S | 445 | $124.2008 | D | 4,925 | D | |
| Common StockF4,F6 | Jul 18, 2018 | S | 1,621 | $125.6029 | D | 3,304 | D | |
| Common StockF5,F6 | Jul 18, 2018 | S | 904 | $126.3953 | D | 2,400 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive.
- F5The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive.
- F6The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions.